BioPharmX Invited to Present at World Preclinical Congress
MENLO PARK, Calif., June 14, 2017 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology, presented results of a three (3) arm preclinical study comparing BPX-01 topical hydrophilic formulation of minocycline, lipophilic minocycline formulation and oral minocyline.
The findings were presented in a poster entitled "Effectiveness and Safety of a Topical Hydrophilic Minocycline Compared to a Topical Lipophilic Minocycline." The poster was presented by BioPharmX Senior Director of Preclinical Drug Development, Usha Nagavarapu, Ph.D., at The Westin Copely Place in Boston, MA on Tuesday. More information and details of the poster can be found on the company's website.
"The study reinforces the efficient penetration and lack of systemic exposure that the hydrophilic BPX-01 may offer over both lipophilic minocycline formulations and oral minocycline." said Kin F. Chan, Ph.D., executive vice president of research and technology at BioPharmX. "BPX-01 delivered minocycline to the pilosebaceous unit where acne resides and could not be traced in plasma."
BioPharmX recently completed a phase 2b clinical study. The data showed BPX-01 2% reduced the number of inflammatory lesions in acne patients by 59% (versus 44% in vehicle) with no serious drug-related side effects, and suggested it may also lessen the severity of lesions. The company plans to begin its phase 3 research later this year.
The American Academy of Dermatology calls acne the "most common skin condition in the United States," affecting up to 50 million Americans. The disease can cause permanent scarring, low self-esteem, depression and anxiety.
AI
